☆ 4.6 Letter

MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma

BRITISH JOURNAL OF HAEMATOLOGY (2010)

Journal

BRITISH JOURNAL OF HAEMATOLOGY

Volume 149, Issue 6, Pages 896-899

Publisher

WILEY-BLACKWELL

DOI: 10.1111/j.1365-2141.2010.08111.x

Keywords

B cells; B lymphocytes; haematological malignancies; lymphomas

Categories

Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Biotechnology & Applied Microbiology

Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies

Marco Ruella, Felix Korell, Patrizia Porazzi, Marcela V. Maus

Summary: Chimeric antigen receptor (CAR)-T cells have shown great potential in treating blood cancers, but resistance to this therapy remains a challenge. This review summarizes the mechanisms of resistance to CAR-T cell immunotherapy, including CAR-T cell dysfunction, tumor resistance, and the immunosuppressive tumor microenvironment. It also discusses current research strategies to overcome these resistance mechanisms.

NATURE REVIEWS DRUG DISCOVERY (2023)

Add to Collection

Article Multidisciplinary Sciences

Predicted limited redistribution of T cells to secondary lymphoid tissue correlates with increased risk of haematological malignancies in asplenic patients

Aleksandra E. Kmieciak, Liam Brown, Mark C. Coles, Jonathan Wagg, Alex Phipps, Eamonn A. Gaffney

Summary: Studies have shown that splenectomy leads to a decrease in both the number and concentration of T cells in remaining lymphoid tissue, suggesting insufficient compensation for the loss of spleen's immune surveillance function, potentially increasing the risk of haematological malignancies in patients without a spleen.

SCIENTIFIC REPORTS (2021)

Add to Collection

Review Cell Biology

Immune-epigenetic crosstalk in haematological malignancies

Hera Wong, Ryohichi Sugimura

Summary: Haematological malignancies are a diverse group of cancers that can occur at any stage of hematopoiesis. Chronic inflammation induced by inflammatory cytokines activates signaling pathways in malignant cells, leading to cancer stem cell phenotypes and disease progression. Studying the molecular mechanisms of immune cell interaction with malignant cells could provide new avenues for targeted therapies for haematological malignancies.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2023)

Add to Collection

Article Oncology

B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity

Aubrey S. Smith, Hannah M. Knochelmann, Megan M. Wyatt, Guillermo O. Rangel Rivera, Amalia M. Rivera-Reyes, Connor J. Dwyer, Michael B. Ware, Anna C. Cole, David M. Neskey, Mark P. Rubinstein, Bei Liu, Jessica E. Thaxton, Eric Bartee, Chrystal M. Paulos

Summary: TLR agonists can be repurposed ex vivo to condition T cells, improving immunotherapy and revealing the vital role of B cells in the generation of potent CD8(+) T cell-based therapies.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Clinical Proteomics of Biofluids in Haematological Malignancies

Katie Dunphy, Kelly O'Mahoney, Paul Dowling, Peter O'Gorman, Despina Bazou

Summary: Advancements in proteomic and clinical technologies have led to an increase in cancer-related biomarkers identified from biofluids, showing promising potential for diagnosis and prognosis. These biofluid proteomes are dynamic and can detect disease-related protein biomarkers, with ongoing efforts focused on developing novel minimally invasive markers for therapeutic monitoring. Progress has been made in biomarker diagnostics for hematologic malignancies, but there is a need for further research in this area.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Oncology

Targeting hypoxia in solid and haematological malignancies

Bill Harris, Sana Saleem, Natalie Cook, Emma Searle

Summary: Tumour hypoxia is a well-known phenomenon that is associated with aggressive disease behavior and poor prognosis in cancer patients. It stimulates the activation of various downstream factors that influence angiogenesis, treatment resistance, immune surveillance, and metastasis. Despite promising pre-clinical data, targeting hypoxia in clinical trials has proven challenging. Further research is needed to understand the effect of hypoxia in humans and develop effective therapeutic strategies.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Hematology

Haematological Malignancies in Older People 1 A comprehensive approach to therapy of haematological malignancies in older patients

Raul Cordoba, Toby A. Eyre, Heidi D. Klepin, Tanya M. Wildes, Valentin Goede

Summary: Haematological malignancies are a diverse group of diseases with increasing incidence with age, particularly reaching a peak at 75-99 years, but overall survival is low for older adults, especially with acute leukaemias. Understanding the heterogeneity in outcomes, treatment challenges, and management of frailty and comorbidities among older patients can help physicians better address the burden and mortality of haematological cancers in aging populations.

LANCET HAEMATOLOGY (2021)

Add to Collection

Article Oncology

Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer

Richard A. Miller, Jason John Luke, Shenshen Hu, Suresh Mahabhashyam, William B. Jones, Thomas Marron, Jaime R. Merchan, Brett G. M. Hughes, Stephen B. Willingham

Summary: This study evaluated the effects of Mupadolimab on immune cells and found that it activates B cells and stimulates the production of antigen specific antibodies. These results support further investigation of Mupadolimab as an immunotherapy for cancer and its potential use as a vaccine adjuvant.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Activated B cells suppress T-cell function through metabolic competition

Nobuhiko Imahashi, Rafet Basar, Yuefan Huang, Fang Wang, Natalia Baran, Pinaki Prosad Banerjee, Junjun Lu, Ana Karen Nunez Cortes, Nadima Uprety, Emily Ensley, Luis Muniz-Feliciano, Tamara J. Laskowski, Judy S. Moyes, May Daher, Mayela Mendt, Lucila N. Kerbauy, Mayra Shanley, Li Li, Francesca Lorraine Wei Inng Lim, Hila Shaim, Ye Li, Marina Konopleva, Michael Green, Jennifer Wargo, Elizabeth J. Shpall, Ken Chen, Katayoun Rezvani

Summary: This study shows that activated B cells suppress T-cell responses through metabolic competition, including increased oxygen consumption and glucose deprivation. These findings provide new insights into immunometabolism and its potential implications for cancer immunotherapy.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Review Oncology

Application of double-negative T cells in haematological malignancies: recent progress and future directions

Xingchi Chen, Dongyao Wang, Xiaoyu Zhu

Summary: Haematologic malignancies are common and deadly worldwide. Current treatment methods such as allogeneic haematopoietic stem cell transplantation have limitations. Adoptive cellular therapy, especially using double-negative T cells, shows great potential in treating haematologic malignancies.

BIOMARKER RESEARCH (2022)

Add to Collection

Article Oncology

Molnupiravir is effective in patients with haematological malignancies

Lukasz Bolkun, Bartosz Pula, Agnieszka Kolkowska-Lesniak, Marta Morawska, Edyta Cichocka, Grzegorz Charlinski, Bartosz Garus, Sebastian Giebel, Jaroslaw Piszcz, Joanna Drozd-Sokolowska, Jacek Kwiatkowski, Monika Biernat, Iwona Hus, Ewa Lech-Maranda, Monika Dlugosz-Danecka, Krzysztof Giannopoulos, Tomasz Wrobel

Summary: Patients with hematologic malignancies are at high risk of severe infectious complications and death from SARS-CoV-2 infection. Their immune deficits and the treatment used make COVID-19 vaccination less effective. Molnupiravir has shown significant benefits in reducing hospitalization and death in COVID-19 patients, including those with hematologic malignancies.

INTERNATIONAL JOURNAL OF CANCER (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies

Rachel L. Mynott, Ali Habib, Oliver G. Best, Craig T. Wallington-Gates

Summary: Haematological malignancies are diverse types of cancers affecting the bone marrow, blood, or lymph nodes, and while progress has been made in treatment, many are still incurable. Ferroptosis, a type of cell death that relies on iron and lipid oxidation, shows promise in inducing cancer cell death, especially in cancers resistant to traditional therapies. The main challenges for ferroptosis-inducing therapies are drug delivery and toxicity to healthy tissue, but the use of tumour-targeting and precision medicines, along with nanotechnologies, may help overcome these obstacles. This review discusses the current state of ferroptosis in haematological malignancies and the potential of ferroptosis nanotechnologies in treating diseases like multiple myeloma, lymphoma, and leukemia.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Hematology

Familial aggregation of early-onset haematological malignancies

Rosa Ronkko, Elli Hirvonen, Nea Malila, Outi Kilpivaara, Ulla Wartiovaara-Kautto, Janne Pitkaniemi

Summary: The study found significantly elevated standardized incidence ratios among first-degree relatives of patients with common haematological malignancies, with siblings having the highest risk for Hodgkin lymphoma and acute myeloid leukaemia. The findings suggest a role of shared aetiological factors in some families, emphasizing the importance of family history in clinical care for patients with early-onset haematological malignancies.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Oncology

Culturing adequate CAR-T cells from less peripheral blood to treat B-cell malignancies

Lu Han, Jian Zhou, Linlin Li, Keshu Zhou, Lingdi Zhao, Xinghu Zhu, Qingsong Yin, Yufu Li, Hongqin You, Jishuai Zhang, Yongping Song, Quanli Gao

Summary: A novel method for CAR-T cell preparation from small volumes of peripheral blood has been developed, providing an alternative means of CAR-T cell generation for patients ineligible for leukapheresis. This method resulted in successful expansion of CAR-T cells and promising outcomes in patients with B-cell malignancies.

CANCER BIOLOGY & MEDICINE (2021)

Add to Collection

Article Microbiology

CD4+ T cells reverse surface antigen persistence in a mouse model of HBV replication

Jacob T. Bailey, Safiehkhatoon Moshkani, Catherine Rexhouse, Jesse L. Cimino, Michael D. Robek

Summary: Hepatitis B virus (HBV) is a leading cause of viral hepatitis with a significant impact on global mortality. Although there is currently no highly effective cure for chronic HBV infection, immunotherapy has emerged as a potential treatment option due to its association with HBV-specific immune responses. However, the lack of suitable animal models for studying HBV has posed challenges in understanding the natural immune response to the virus. This study used a mouse model of HBV replication and demonstrated the crucial role of CD4(+) T cells in the antibody-mediated clearance of HBsAg, as well as their ability to reverse HBsAg persistence.

MICROBIOLOGY SPECTRUM (2023)

Add to Collection

Letter Hematology

Long non-coding RNAs associated with transcriptomic signatures and treatment outcome in diffuse large B-cell lymphoma

Gerben Duns, Melanie Winkle, Lauren Chong, Daisuke Ennishi, Ryan D. D. Morin, Arjan Diepstra, David W. W. Scott, Joost L. L. Kluiver, Christian Steidl, Anke van den Berg

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Bibliography Oncology

Obituary-Pieter Van Vlierberghe (1980-2022)

Malgorzata Dawidowska, Agnieszka Dzikiewicz-Krawczyk, Natalia Rozwadowska, Panagiotis Ntziachristos, Joost Kluiver, Anke van den Berg, Reiner Siebert, Maciej Giefing

LEUKEMIA (2023)

Add to Collection

Review Oncology

A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments

Fenneke Zwierenga, Bianca A. M. H. van Veggel, Anke Van den Berg, Harry J. M. Groen, Lili Zhang, Matthew R. Groves, K. Kok, E. F. Smit, T. Jeroen N. Hiltermann, Adrianus J. de Langen, Anthonie J. Van der Wekken

Summary: This article provides a comprehensive assessment of drug sensitivity in vitro and in clinical settings for EGFRex20+ mutations in NSCLC. The activating A763_Y764insFQEA mutation shows better tumor response compared to mutations in other regions, suggesting the need for different treatment approaches. Classification beyond exon-based categories is necessary due to marked differences in treatment responses among EGFRex20+ mutations.

CANCER TREATMENT REVIEWS (2023)

Add to Collection

Article Biotechnology & Applied Microbiology

Inhibition of the glutamate-cysteine ligase catalytic subunit with buthionine sulfoximine enhances the cytotoxic effect of doxorubicin and cyclophosphamide in Burkitt lymphoma cells

Marta Kazimierska, Aleksandra Lesniewska, Anja Bakker, Arjan Diepstra, Marta Elzbieta Kasprzyk, Marta Podralska, Karolina Rassek, Joost Kluiver, Anke van den Berg, Natalia Rozwadowska, Agnieszka Dzikiewicz-Krawczyk

Summary: This study found that GCLC plays an important role in Burkitt lymphoma, and inhibiting GCLC can decrease the viability of BL cells. Buthionine sulfoximine has a growth-inhibiting effect on BL cells and can enhance the cytotoxicity of doxorubicin and cyclophosphamide.

JOURNAL OF APPLIED GENETICS (2023)

Add to Collection

Letter Oncology

Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA

Nick Veltmaat, Yujie Zhong, Filipe Montes de Jesus, Geok Wee Tan, Johanna A. A. Bult, Martijn M. Terpstra, Pim G. N. J. Mutsaers, Wendy B. C. Stevens, Rogier Mous, Joost S. P. Vermaat, Martine E. D. Chamuleau, Walter Noordzij, Erik A. M. Verschuuren, Klaas Kok, Joost L. Kluiver, Arjan Diepstra, Wouter J. Plattel, Anke Van den Berg, Marcel Nijland

Summary: The study investigates the use of cfDNA for genomic profiling of PTLD, and explores its potential as a screening tool. Analysis showed that 41% of patients had EBV-positive tumors and 76% had stage IV disease. The study provides important insights into the genetic variations and EBV infection in PTLD.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2023)

Add to Collection

Correction Oncology

Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes (vol 36, pg 2835, 2023)

Sonja I. Berndt, Joseph Vijai, Yolanda Benavente, Nicola J. Camp, Alexandra Nieters, Zhaoming Wang, Karin E. Smedby, Geffen Kleinstern, Henrik Hjalgrim, Caroline Besson, Christine F. Skibola, Lindsay M. Morton, Angela R. Brooks-Wilson, Lauren R. Teras, Charles Breeze, Joshua Arias, Hans-Olov Adami, Demetrius Albanes, Kenneth C. Anderson, Stephen M. Ansell, Bryan Bassig, Nikolaus Becker, Parveen Bhatti, Brenda M. Birmann, Paolo Boffetta, Paige M. Bracci, Paul Brennan, Elizabeth E. Brown, Laurie Burdett, Lisa A. Cannon-Albright, Ellen T. Chang, Brian C. H. Chiu, Charles C. Chung, Jacqueline Clavel, Pierluigi Cocco, Graham Colditz, Lucia Conde, David V. Conti, David G. Cox, Karen Curtin, Delphine Casabonne, Immaculata De Vivo, Arjan Diepstra, W. Ryan Diver, Ahmet Dogan, Christopher K. Edlund, Lenka Foretova, Joseph F. Fraumeni, Attilio Gabbas, Herve Ghesquieres, Graham G. Giles, Sally Glaser, Martha Glenn, Bengt Glimelius, Jian Gu, Thomas M. Habermann, Christopher A. Haiman, Corinne Haioun, Jonathan N. Hofmann, Theodore R. Holford, Elizabeth A. Holly, Amy Hutchinson, Aalin Izhar, Rebecca D. Jackson, Ruth F. Jarrett, Rudolph Kaaks, Eleanor Kane, Laurence N. Kolonel, Yinfei Kong, Peter Kraft, Anne Kricker, Annette Lake, Qing Lan, Charles Lawrence, Dalin Li, Mark Liebow, Brian K. Link, Corrado Magnani, Marc Maynadie, James McKay, Mads Melbye, Lucia Miligi, Roger L. Milne, Thierry J. Molina, Alain Monnereau, Rebecca Montalvan, Kari E. North, Anne J. Novak, Kenan Onel, Mark P. Purdue, Kristin A. Rand, Elio Riboli, Jacques Riby, Eve Roman, Gilles Salles, Douglas W. Sborov, Richard K. Severson, Tait D. Shanafelt, Martyn T. Smith, Alexandra Smith, Kevin W. Song, Lei Song, Melissa C. Southey, John J. Spinelli, Anthony Staines, Deborah Stephens, Heather J. Sutherland, Kaitlyn Tkachuk, Carrie A. Thompson, Herve Tilly, Lesley F. Tinker, Ruth C. Travis, Jenny Turner, Celine M. Vachon, Claire M. Vajdic, Anke Van den Berg, David J. Van den Berg, Roel C. H. Vermeulen, Paolo Vineis, Sophia S. Wang, Elisabete Weiderpass, George J. Weiner, Stephanie Weinstein, Nicole Wong Doo, Yuanqing Ye, Meredith Yeager, Kai Yu, Anne Zeleniuch-Jacquotte, Yawei Zhang, Tongzhang Zheng, Elad Ziv, Joshua Sampson, Nilanjan Chatterjee, Kenneth Offit, Wendy Cozen, Xifeng Wu, James R. Cerhan, Stephen J. Chanock, Susan L. Slager, Nathaniel Rothman

LEUKEMIA (2023)

Add to Collection

Article Oncology

CRISPR/Cas9 screen for genome-wide interrogation of essential MYC-bound E-boxes in cancer cells

Marta Kazimierska, Marta Podralska, Magdalena Zurawek, Tomasz Wozniak, Marta Elzbieta Kasprzyk, Weronika Sura, Wojciech Losiewski, Iwona Ziolkowska-Suchanek, Joost Kluiver, Anke van den Berg, Natalia Rozwadowska, Agnieszka Dzikiewicz-Krawczyk

Summary: The transcription factor MYC plays a crucial role in the development and maintenance of various types of cancer by binding to specific E-box sequences in the genome to regulate gene expression. Through the use of CRISPR/Cas9 technology and high-throughput screening, this study identified essential MYC-regulated genes involved in pathways associated with cancer development. This research provides a novel approach to explore MYC-dependent vulnerabilities in cancer cells, which is of significant importance.

MOLECULAR ONCOLOGY (2023)

Add to Collection

Article Oncology

A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics

Johanna A. A. Bult, Francien Huisman, Yujie Zhong, Nick Veltmaat, Joost Kluiver, Sanne H. Tonino, Joost S. P. Vermaat, Martine E. D. Chamuleau, Arjan Diepstra, Anke van den Berg, Wouter J. Plattel, Mirian Brink, Marcel Nijland

Summary: This population-based study reveals the clinical characteristics associated with transformation and survival after transformation of marginal zone lymphoma (tMZL). Elevated LDH and nodal MZL subtype at MZL diagnosis increase the risk of transformation, while radiotherapy reduces the risk. Age >60 years and (immuno)chemotherapy before transformation are associated with an increased risk of relapse and mortality. Two-year progression-free survival and overall survival are higher for R-(mini)CHOP-treated tMZL patients.

BLOOD CANCER JOURNAL (2023)

Add to Collection

Article Oncology

Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy

Lydia Lee, Wen Chean Lim, Daria Galas-Filipowicz, Kent Fung, Julia Taylor, Dominic Patel, Zulaikha Akbar, Elena Alvarez Mediavilla, Patrycja Wawrzyniecka, Debarati Shome, Rogier M. Reijmers, Trillian Gregg, Leigh Wood, William Day, Virginie Cerec, Mathieu Ferrari, Simon Thomas, Shaun Cordoba, Shimobi Onuoha, Nushmia Khokhar, Vijay Peddareddigari, Muhammad Al-Hajj, Jim Cavet, Sonja Zweegman, Manuel Rodriguez-Justo, Kwee Yong, Martin Pule, Rakesh Popat

Summary: In this study, a ligand-based CAR targeting two myeloma antigens was constructed and evaluated in a clinical trial. The results showed that the APRIL CAR was well tolerated, but the clinical responses were disappointing. Comparing with other BCMA CARs, the APRIL CAR exhibited functional deficiencies due to reduced target binding by cell-expressed ligand.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.